A biocompatible, antimicrobial adhesive for corneal repair and grafting could replace sutures and conventional adhesives that have bad side effects.

An assistant professor of bioengineering at the University of California-Riverside has developed an adhesive that rapidly integrates corneal cells to speed healing and reduce the chances of secondary infection.

The breakthrough by Iman Noshadi also reduces complications that increase the risk, cost, and healing time of eye injuries and corneal transplants.

Of the 2.4 million eye injuries annually in the United States, 600,000 are open globe corneal tears, leading to blindness in some cases. There are also around 40,000 corneal grafting procedures performed each year.

The current standards of care for corneal repair are sutures and cyanoacrylate glue, both of which are associated with complications and costs, during and after the procedure.

Sutures, used for larger tears and grafting, can cause astigmatism, vascularization, and infections. Cyanoacrylate glue, which is not FDA approved, can be used only for tiny perforations, has low biocompatibility, cytotoxicity, opacity, and causes infections and cataract – all needing additional care and cost.

"There is no FDA-approved material platform to replace the present techniques for corneal repair effectively," said Noshadi. "Our technology addresses all these issues, resulting in reduced operative and post-operative costs."

The UC Riverside product should solve these secondary problems with its biocompatibility, high adhesion, flexibility, and high strength. It will not accidentally loosen or fall off and its antimicrobial properties will help prevent infections. Because the adhesive is transparent, it will help restore vision more quickly, as well.

The new material is a biodegradable polymer that combines a choline-based ionic liquid-an organic salt with high water solubility and electrochemical properties- with polyethylene glycol, a biocompatible compound widely used in medical applications. These adhesives can adhere quickly and strongly to the tissues. Its biocompatible nature allows long-term regeneration of corneal cells.

"Our gel will result in a safer procedure that will improve the patient's quality of life with better health outcomes by preventing visual acuity loss or blindness. The simpler procedure will save time, reduce operative costs, and eliminate corrective surgery and need for extensive post-operative care," said Noshadi, who, with a $250,000 grant from the National Science Foundation, hopes to have the product on the market by 2026.

With the funding, Noshadi's research group will test the material's tissue adhesion, biocompatibility, flexibility, transparency, and antibacterial properties. Then, the researchers will test its performance on corneal tears and study its effects on corneal cells, as well as the migration of corneal cells into the bioadhesive over time.

When the UC Riverside corneal adhesive is approved for the market, Noshadi expects that corneal transplants will be more affordable, less dangerous, easier to recover from, and more available to people who need them.

LET Your Friends SEE This Great Potential -SHARE on Social Media…